CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Feature|Articles|September 18, 2026
Vitamin K Refusals Are Rising: What Payers Need to Know
Author(s)Sabrina McCrear
Fact checked by: Laura Joszt, MA, William Schaffner, MD
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Advertisement
Advertisement
Vitamin K shot refusals among newborns in the US have risen 77%, from 2.92% in 2017 to 5.18% in 2024, leading clinicians interviewed for this piece to believe broader
Related to this article
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement